- Patent Number:
10492,717
- Appl. No:
15/034062
- Application Filed:
November 04, 2014
- Abstract:
A method includes receiving multiple compound muscle action potential values (CMAPs), wherein each CMAP is an onset latency, a peak latency, a conduction velocity, or a response amplitude measured from a baseline; for each of the CMAPs and for each of a number parameters calculated from the CMAPs, determining a corresponding demyelinating boundary value using a normal value from a preselected population; determining whether each of the CMAPs and each of the parameters exceeds the corresponding demyelinating boundary value; determining one or more demyelinated nerve pathways based on which of the CMAPs and the parameters exceeds the corresponding demyelinating boundary value; indicating on a display which of the CMAPs and the parameters exceed the corresponding demyelinating boundary value; and displaying, in pictorial form, an anatomical diagram indicating the demyelinated nerve pathways.
- Inventors:
The Research Foundation of State University of New York (Albany, NY, US)
- Assignees:
The Research Foundation of State University of New York (Albany, NY, US)
- Claim:
1. A non-transitory computer-readable medium, having computer-executable instructions stored thereon, that in response to execution by a computing device that contains a processor, cause the computing device to perform operations comprising: receive one or more values from a plurality of compound muscle action potentials (CMAPs), wherein the one or more values is selected from a group consisting of an onset latency, a peak latency, a conduction velocity, a response amplitude measured from a baseline, and a combination thereof; for each of the one or more values from the plurality of CMAPs, determine a corresponding demyelinating boundary value using a normal value from a preselected population, wherein the corresponding demyelinating boundary value is determined by one or more of the following approaches: (a) a demyelinating Z regression approach, comprising determining a corresponding demyelinating regression boundary value by regression based on at least one of age or height; (b) a percentage approach, comprising determining an upper limit of normal range and determining a corresponding demyelinating percentage boundary value as a percentage value, greater than 100%, of the upper limit of normal range; and (c) a specificity approach, comprising determining a corresponding demyelinating specificity boundary value as a minimum value for which demyelination is determined in the preselected population at a preselected level of specificity, wherein the preselected level of specificity is at least 95%; determine whether each of the one or more values from the plurality of CMAPs exceeds the corresponding demyelinating boundary value; determine one or more demyelinated nerve pathways based on which of the one or more values from the plurality of CMAPs exceeds the corresponding demyelinating boundary value; indicate on an interface each of the one or more values from the plurality of CMAPs and which of the one or more values from the plurality of CMAPs exceed the corresponding demyelinating boundary value for each approach that is used, wherein the interface further evaluates the one or more values relative to the corresponding demyelinating boundary value for each approach; and display, in pictorial form, an anatomical diagram indicating the one or more demyelinated nerve pathways on the interface.
- Claim:
2. The non-transitory computer-readable medium of claim 1 , wherein determining the upper limit of normal range comprises selecting a number of standard deviations and determining the upper limit as a value corresponding to a mean for the preselected population plus the number of standard deviations for the preselected population.
- Claim:
3. The non-transitory computer-readable medium of claim 1 , wherein the pre-selected level of specificity is 100%.
- Claim:
4. The non-transitory computer-readable medium of claim 1 , wherein the operations further comprise, for each of the one or more values from the plurality of CMAPs, determine a corresponding axonal boundary value using a normal value for the preselected population.
- Claim:
5. The non-transitory computer-readable medium of claim 1 , wherein an axonal range is between an axonal boundary value and the corresponding demyelinating boundary value and wherein the operations further comprise displaying on the anatomical diagram which of the one or more demyelinated nerve pathways are in the axonal range.
- Claim:
6. The non-transitory computer-readable medium of claim 1 , wherein the plurality of CMAPs comprises a plurality of soleus CMAPs.
- Claim:
7. The non-transitory computer-readable medium of claim 1 , wherein the plurality of CMAPs comprises at least one CMAP selected from a femoral CMAP, a tibial CMAP, or a peroneal CMAP.
- Claim:
8. The non-transitory computer-readable medium of claim 1 , wherein the plurality of CMAPs is recorded at a soleus, abductor hallucis brevis , or a combination thereof.
- Claim:
9. The non-transitory computer-readable medium of claim 1 , wherein the plurality of CMAPs comprises at least one CMAP elicited by neuromagnetic stimulation.
- Claim:
10. The non-transitory computer-readable medium of claim 9 , wherein the plurality of CMAPs comprises at least one CMAP elicited by neuromagnetic stimulation of a distal cauda equina.
- Claim:
11. The non-transitory computer-readable medium of claim 1 , wherein the corresponding demyelinating boundary value is determined by two or more of the demyelinating Z regression approach, the percentage approach, and the specificity approach.
- Claim:
12. The non-transitory computer-readable medium of claim 11 , wherein the corresponding demyelinating boundary value is determined by each of the demyelinating Z regression approach, the percentage approach, and the specificity approach.
- Claim:
13. A computer-based method, wherein a plurality of actions is performed by a processor operating within a computing device, the plurality of actions comprising: receiving one or more values from a plurality of compound muscle action potentials (CMAPs), wherein the one or more values is selected from a group consisting of an onset latency, peak latency, conduction velocity, a response amplitude measured from a baseline, and a combination thereof; for each of the one or more values from the plurality of CMAPs, determining a corresponding demyelinating boundary value using a normal value from a preselected population, wherein the corresponding demyelinating boundary value is determined by one or more of the following approaches: (a) a demyelinating Z regression approach, comprising determining a corresponding demyelinating regression boundary value by regression based on at least one of age or height; (b) a percentage approach, comprising determining an upper limit of normal range and determining a corresponding demyelinating percentage boundary value as a percentage value, greater than 100%, of the upper limit of normal range; and (c) a specificity approach, comprising determining a corresponding demyelinating specificity boundary value as a minimum value for which demyelination is determined in the preselected population at a preselected level of specificity, wherein the preselected level of specificity is at least 95%; determining whether each of the one or more values from the plurality of CMAPs exceeds the corresponding demyelinating boundary value; determining one or more demyelinated nerve pathways based on which of the one or more values from the plurality of CMAPs exceeds the corresponding demyelinating boundary value; indicating on an interface each of the one or more values from the plurality of CMAPs and which of the one or more values from the plurality of CMAPs exceed the corresponding demyelinating boundary value for each approach that is used, wherein the interface further evaluates the one or more values relative to the corresponding demyelinating boundary value for each approach; and displaying, in pictorial form, an anatomical diagram indicating the one or more demyelinated nerve pathways on the interface.
- Claim:
14. The computer-based method of claim 13 , wherein the plurality of CMAPs is recorded at a soleus, abductor hallucis brevis, or a combination thereof.
- Claim:
15. The computer-based method of claim 13 , wherein the plurality of CMAPs comprises at least one CMAP elicited by neuromagnetic stimulation.
- Claim:
16. The computer-based method of claim 15 , wherein the plurality of CMAPs comprises at least one CMAP elicited by neuromagnetic stimulation of a distal cauda equina.
- Claim:
17. The computer-based method of claim 13 , wherein the corresponding demyelinating boundary value is determined by two or more of the demyelinating Z regression approach, the percentage approach, and the specificity approach.
- Claim:
18. The computer-based method of claim 17 , wherein the corresponding demyelinating boundary value is determined by each of the demyelinating Z regression approach, the percentage approach, and the specificity approach.
- Patent References Cited:
2004/0038311 February 2004 Pestronk
2005/0113877 May 2005 Spinelli et al.
2007/0282217 December 2007 McGinnis
2008/0071191 March 2008 Kelleher
2009/0204175 August 2009 Zanella
2010/0222665 September 2010 Roberts
2010/0286554 November 2010 Davis et al.
2011/0053956 March 2011 Leahy et al.
2012/0115138 May 2012 Deigner et al.
- Other References:
International Search Report and Written Opinion issued (dated Mar. 3, 2015) in corresponding International Application No. PCT/US2014/063956. cited by applicant
- Primary Examiner:
Fernandes, Patrick
- Attorney, Agent or Firm:
Haug Partners LLP
- Accession Number:
edspgr.10492717
Processing Request
No Comments.